dalcetrapib (JTT-705)

Mechanism of action

• inhibits cholesterol ester transfer protein (CETP)
• increases HDL cholesterol

Clinical trials

[1]

• study characteristics
  • 15,871 patients with recent acute coronary syndrome
  • mean age, 60; about 80% men
  • median follow-up of 31 months
  • trial was stopped for futility
  • primary endpoint: death from cardiovascular event
• treatment:
  • randomized to dalcetrapib or placebo between 4 & 12 weeks after the index event
• results:
  • dalcetrapib markedly increased in HDL cholesterol
  • no significant effect on the primary endpoint (or any of its components) compared with placebo

More general terms

• cholesteryl ester transfer protein (CETP) inhibitor
• amide
• thiol ester

Additional terms

• cholesteryl ester transfer protein; lipid transfer protein I (CETP)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6918540
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=49849445